# Vertex Pharmaceuticals has reached an agreement with the Competition Commission, resolving a pricing dispute over its cystic fibrosis treatment. The company had faced allegations of excessive pricing for its life-saving drug, Trikafta. Under the agreement, Vertex will reduce the price of Trikafta in South Africa, making it more accessible to patients. Financial help will also be available for eligible patients. The commission has concluded its investigation but retains the right to take further action if necessary.
Vertex Pharmaceuticals resolves pricing dispute with Competition Commission